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Available online 5 November 2010Hyperornithinemia–hyperammonemia–homocitrullinuria (HHH) syndrome is an autosomal
recessive disorder caused by a defect in the mitochondrial ornithine transporter, leading to
accumulation of ornithine (Orn), homocitrulline (Hcit) and ammonia. Progressive
neurological regression whose pathogenesis is not well established is common in this
disease. The present work investigated the in vivo effects of intracerebroventricular
administration of Orn and Hcit on important parameters of oxidative stress and energy
metabolism in cerebral cortex from young rats. Orn and Hcit significantly increased
thiobarbituric acid-reactive substances values and carbonyl formation, indicators of lipid
and protein oxidative damage, respectively. Furthermore, N-acetylcysteine and the
combination of the free radical scavengers ascorbic acid plus α-tocopherol attenuated the
lipid oxidation and totally prevented the protein oxidative damage provoked by Orn and
Hcit, suggesting that reactive species were involved in these effects. Hcit, but not Orn
administration, also decreased glutathione concentrations, aswell as the activity of catalase
and glutathione peroxidase, indicating that Hcit provokes a reduction of brain antioxidant
defenses. As regards to the parameters of energy metabolism, we verified that Orn and Hcit
significantly inhibited the citric acid cycle function (inhibition of CO2 synthesis from [1-14C]
acetate), the aerobic glycolytic pathway (reduced CO2 production from [U-14C] glucose) and
complex I–III activity of the respiratory chain. Hcit also inhibited the activity of aconitase, an
enzyme very susceptible to free radical attack. Taken together, our data indicate that
mitochondrial homeostasis is disturbed by Orn and especially by Hcit. It is presumed thatKeywords:
Ornithine
Homocitrulline
Hyperornithinemia–
hyperammonemia–
homocitrullinuria syndrome
Oxidative stress
Energy metabolism
Cerebral cortexquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Rua Ramiro Barcelos, 2600-Anexo-
+55 51 21018010.
jner).
ia–hyperammonemia–homocitrullinuria; Orn, ornithine; Hcit, homocitrulline; ICV,
the Elsevier OA license.
236 B R A I N R E S E A R C H 1 3 6 9 ( 2 0 1 1 ) 2 3 5 – 2 4 4the impairment of brain bioenergetics and the oxidative damage induced by these
metabolites may possibly contribute to the brain deterioration and neurological
symptoms affecting patients with HHH syndrome.
© 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Hyperornithinemia–hyperammonemia–homocitrullinuria
(HHH) syndrome (OMIM 238970) is an autosomal recessive
disorder due to mutation in the gene that encodes the
mitochondrial ornithine (Orn) transporter ORNT1 (SLC25A15)
(Camacho et al., 1999; Fell et al., 1974; Korman et al., 2004;
Tessa et al., 2009; Valle and Simell, 2001). The inability to
import Orn from the cytosol into the mitochondria results in
intramitochondrial Orn deficiency and a functional impair-
ment of the urea cycle at the level of ornithine transcarba-
mylase, with consequent hyperammonemia. The defect also
gives rise to cytoplasmatic accumulation of Orn resulting in
hyperornithinemia. In the absence of intramitochondrial Orn,
accumulating carbamoyl phosphate may condense with
lysine to form homocitrulline (Hcit) leading to homocitrulli-
nuria (Valle and Simell, 2001).
The clinical features of neurological symptoms in HHH
syndrome are very peculiar since, besides some unspecific
signs similar to the others urea cycle defects (hypotonia,
seizures, ataxia, coma, etc.), patients exhibit a pyramidal
syndrome with progressive spastic paraplegia. Neuropatho-
logical findings include multiple, nonspecific T2 hyperintense
foci in occipital, parietal and frontal white matter, with
subcortical and cortical atrophy associated with swelling
typically seen in demyelinating diseases (Al-Hassnan et al.,
2008). It should be stressed that among the urea cycle defects,
pyramidal dysfunction is also present in argininemia and
therefore both disorders share a common characteristic
clinical picture (Valle and Simell, 2001).
The mechanisms of central nervous system (CNS) impair-
ment in HHH syndrome are poorly known (Palmieri, 2008;
Salvi et al., 2001), although it has been hypothesized that the
neurologic damage presented by the patients are probably
secondary to the episodic hyperammonemia. However, chron-
ic accumulation of Orn, Hcit and other metabolic factors
cannot be ruled out as contributing causes of the neurological
symptoms and brain abnormalities seen in these patients,
especially during crises of metabolic decompensation, in
which the concentrations of these metabolites dramatically
increase. It seems therefore justifiable to investigate the role
of these accumulating metabolites on important systems
necessary for normal CNS function that may lead to a better
understanding of the relationship between the clinical fea-
tures and the biochemical abnormalities in this disorder.
In this scenario, we have recently demonstrated that Orn
and Hcit elicit in vitro lipid peroxidation, protein oxidative
damage and decrease glutathione (GSH) levels and disrupt
energy metabolism in brain of young rats (Amaral et al., 2009;
Viegas et al., 2009).
In the present study we investigated whether in vivo
intracerebroventricular (ICV) administration of Orn and Hcit
to rats could induce lipid (thiobarbituric acid-reactive sub-stances) and protein (sulfhydryl content and carbonyl
formation) oxidative damage, as well as affect the antioxi-
dant defenses (reduced glutathione levels and the activities
of the antioxidant enzymes glutathione peroxidase, catalase
and superoxide dismutase) and nitrates and nitrites produc-
tion. We also tested the influence of in vivo ICV administra-
tion of these amino acids on parameters of aerobic
glycolysis (CO2 production from [U-14C] glucose), citric acid
cycle (CAC) activity (CO2 production from [1-14C] acetate and
the enzyme activities of the CAC), electron transfer flow
through the respiratory chain (complex I–IV activities), as
well as on intracellular ATP transfer (creatine kinase
activity) and the activity of Na+, K+-ATPase, an important
enzyme necessary for normal neurotransmission, in cerebral
cortex from young rats.2. Results
2.1. Oxidative stress parameters
2.1.1. Orn and Hcit intracerebroventricular administration
induces lipid peroxidation in cerebral cortex
Initially we studied the effect of intracerebroventricular (ICV)
injection of Orn and Hcit on TBA-RS levels in cerebral
cortex. Fig. 1A shows that Orn (37%) and Hcit (43%) induced
lipid peroxidation (TBA-RS increase) in cerebral cortex
30 min after drug infusion [F(2,16)=6.671; p<0.01]. Next, we
examined the effect of i.p. daily injections of N-acetylcys-
teine (NAC: 150 mg/kg), α-tocopherol (40 mg/kg) plus ascor-
bic acid (100 mg/kg), or saline (0.9% NaCl) for 3 days (pre-
treatment), on Orn and Hcit-induced lipid oxidative damage.
As shown in the figure, pre-treatment with NAC fully
prevented the lipoperoxidation induced by Hcit, but only
attenuated the lipid peroxidation caused by Orn. It can be
also seen that pre-treatment with α-tocopherol plus ascorbic
acid partially prevented the lipid peroxidation elicited by
Orn and Hcit (Fig. 1B and C) (Orn: [F(3,20)=3.183; p<0.05];
Hcit: [F(3,18)=4.278; p<0.05]).
2.1.2. Orn and Hcit intracerebroventricular administration
induces protein oxidative damage in cerebral cortex
We also investigated whether oxidation of tissue proteins was
affected by ICV administration of Orn or Hcit, by measuring
carbonyl and sulfhydryl content. Fig. 2A shows that carbonyl
content was significantly enhanced by Orn (90%) and Hcit
(140%) in cerebral cortex [F(2,14)=8.292; p<0.01], indicating
that these compounds cause protein oxidative damage.
However, ICV administration of Orn or Hcit was not able to
affect the sulfhydryl content (nmol/mg protein: n=7; control:
86.26±7.97; Orn: 92.08±5.64; Hcit: 90.89±11.57). It was also
tested the effects of pre-treatment with NAC (150 mg/kg) or α-
tocopherol (40 mg/kg) plus ascorbic acid (100 mg/kg) on Orn-
Fig. 1 – Effect of intracerebroventricular administration of
ornithine (Orn) and homocitrulline (Hcit) on thiobarbituric
acid reactive substances (TBA-RS) levels in rat cerebral
cortex. The animals received a single ICV injection of NaCl
(control group), Orn (5 μmol) or Hcit (1.6 μmol) and were
sacrificed 30 min after injection (panel A). In some
experiments the animals were pre-treated daily i.p. for
3 days with saline (0.9% NaCl), N-acetylcysteine (NAC,
150 mg/kg) or α-tocopherol (Vit E, 40 mg/kg) plus ascorbic
acid (Vit C, 100 mg/kg), received a single ICV injection of NaCl,
Orn (Panel B) or Hcit (panel C) and were sacrificed 30 min
later. Data are represented as means±standard deviation for
five to seven independent experiments (animals) per group
and expressed as nmol mg protein−1. **p<0.01 compared to
control (panel A). *p<0.05 compared to control (animals
pre-treated with saline and injected ICV with NaCl); #p<0.05,
compared to Sal (animals pre-treated with saline and
injected ICV with Orn or Hcit) (panels B and C), ANOVA
followed by Duncan's multiple range test.
Fig. 2 – Effect of intracerebroventricular administration of
ornithine (Orn) and homocitrulline (Hcit) on carbonyl content in
rat cerebral cortex. The animals received a single ICV injection
of NaCl (control group), Orn (5μmol) or Hcit (1.6μmol) andwere
sacrificed 30min after injection (panel A). In some experiments
the animals were pre-treated daily i.p. for 3 days with saline
(0.9% NaCl), N-acetylcysteine (NAC, 150mg/kg) orα-tocopherol
(Vit E, 40mg/kg) plus ascorbic acid (Vit C, 100mg/kg), received a
single ICV injection of NaCl, Orn (Panel B) or Hcit (panel C) and
were sacrificed 30min later. Data are represented as means
±standard deviation for five to seven independent experiments
(animals) per group and expressed as nmol mg protein−1.
*p<0.05 and **p<0.01 compared to control; ##p<0.01 and
###p<0.001, compared to Sal (rats pre-treated with saline and
injected ICV with Orn or Hcit) (panel B and C) (ANOVA followed
by Duncan's multiple range test).
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in carbonyl formation caused by Orn and Hcit was fully
prevented by this pre-treatment, as shown in Fig. 2B and C
(Orn: [F(3,19)=5.114; p<0.01]; Hcit: [F(3,18)=8.666; p<0.01]).
Fig. 4 – Effect of intracerebroventricular administration of
ornithine (Orn) and homocitrulline (Hcit) on CO2 production
from [U-14C] glucose and [1-14C] acetate in rat cerebral cortex.
Values are means±standard deviation for five independent
experiments (animals) per group and expressed as pmol CO2
h−1 g tissue−1. *p<0.05 and **p<0.01, compared to control
(ANOVA followed by Duncan's multiple range test).
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glutathione (GSH) concentrations in cerebral cortex
GSH concentrations measured in cerebral cortex 30 min after
Orn andHcit ICV administration revealed that Hcitmoderately
reduced (15%) the concentrations of GSH after Hcit injection,
whereas Orn did not alter this parameter [F(2,16)=6.608;
p<0.01] (nmol/mg protein: n=6; control: 4.25±0.45; Orn: 3.95
±0.17; Hcit: 3.66±0.14).
2.1.4. Hcit intracerebroventricular administration inhibits
enzymatic antioxidant defenses in cerebral cortex
The next set of experiments was carried out to investigate the
effect of ICV administration of Orn and Hcit on the activities of
the antioxidant enzymes SOD, CAT and GPx. Fig. 3 shows that
onlyHcitwas able to reduce the activities of GPx [F(2,17)=3.786;
p<0.05] and CAT [F(2,18)=8.328; p<0.01], without affecting SOD
activity.Wealso verified thatOrnwasnot able to change anyof
these activities.
2.1.5. Orn and Hcit intracerebroventricular administration
does not affect nitrite and nitrate generation in cerebral cortex
The effect of Orn and Hcit on reactive nitrogen species
generation was assessed by measuring nitrate and nitrite
production. We observed that this parameter was not altered
by Orn and Hcit ICV administration (nmol/mg protein: n=5;
control: 2.88±1.23; Orn: 2.43±0.89; Hcit: 2.15±0.87).
2.2. Parameters of energy metabolism
2.2.1. Intracerebroventricular injection of Orn and Hcit
inhibits CO2 production from glucose and acetate in rat
cerebral cortex
Weinvestigated theeffectof ICV injectionofOrnandHcitonCO2
production from labeled substrates in cortical homogenates.
Fig. 4 shows that CO2 production from [U-14C] glucose was
significantly inhibited byOrn (35%) andHcit (32%) [F(2,12)=5.515;
p<0.05] 30 min after ICV treatment. CO2 formation from [1-14C]Fig. 3 – Effect of intracerebroventricular administration of
ornithine (Orn) and homocitrulline (Hcit) on the activities of
glutathione peroxidase (GPx), catalase (CAT) and superoxide
dismutase (SOD) in rat cerebral cortex. Data are expressed as
means±standard deviation for six to seven independent
experiments (animals). *p<0.05 and **p<0.01, compared to
control (ANOVA followed by Duncan's multiple range test).acetate was also inhibited by Orn (32%) and Hcit (25%)
administration [F(2,12)=11.048; p<0.01]. These results suggest
that the aerobic glycolytic pathway and the CAC activity were
compromised by Orn and Hcit.
2.2.2. Hcit intracerebroventricular administration inhibits
aconitase activity in cerebral cortex
We also evaluated the effect of Orn and Hcit ICV administration
on CAC enzyme activities. We found that Hcit, significantly
inhibited (20%) aconitase activity (μmol NADPH min−1 mg
protein−1: n=6; control: 1339.4±82.9; Orn: 1208.4±135.6; Hcit:
1070.4±96.9), [F(2,14)=8.450, p<0.01], whereas Orn did not alter
this activity. Furthermore, citrate synthase, isocitrate dehydro-
genase, α-ketoglutarate dehydrogenase, succinate dehydroge-
nase, andmalate dehydrogenase activitieswere not changed by
Orn and Hcit administration (results not shown).
2.2.3. Intracerebroventricular injection of Orn and Hcit
inhibits complex I–III activity of the respiratory chain in
cerebral cortex
The next set of experiments was performed to evaluate the
effect of ICV injection of Orn and Hcit on the activities of the
respiratory chain complexes I–III, II, II–III and IV. We found
that complex I–III activity was significantly inhibited by Orn
(20%) and Hcit (26%) [F(2,15)=10.274; p<0.01], with no signif-
icant alteration of the other tested activities of the respiratory
chain (Table 1).
2.2.4. Orn and Hcit intracerebroventricular administration
does not alter creatine kinase and Na+, K+-ATPase activities in
cerebral cortex
We also examined the effect of Orn and Hcit ICV administra-
tion on the activities of creatine kinase (CK) and synaptic
membrane Na+, K+-ATPase prepared from cerebral cortex. We
observed that these metabolites did not change these
activities (CK: μmol creatine min−1 mg protein−1: n=7; control:
4.33±0.81; Orn: 5.31±0.97; Hcit: 4.48±0.67; NaK: nmol Pi min−1
Table 1 – Effect of intracerebroventricular injection of
ornithine (Orn) and homocitrulline (Hcit) on the activities
of respiratory chain complexes in cerebral cortex from
young rats.
Complex
I–III
Complex
II
Complex
II–III
Complex
IV
Control 15.6±1.60 1.99±0.28 14.7±1.71 159±43.4
Orn 12.5±1.07 ⁎⁎ 2.05±0.59 15.7±3.82 168±56.2
Hcit 11.6±2.03 ⁎⁎ 2.22±0.57 16.1±3.78 176±26.9
Values aremeans±standard deviation for six to seven independent
(animals) experiments per group performed in triplicate. The
activities of complexes I–III, II, II–III and IV are expressed as nmol.
min−1 mg protein−1.
⁎⁎ p<0.01, compared to control (Duncan's multiple range test)
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258.3±28.2).3. Discussion
Patients affected by this HHH syndrome commonly have
neurological dysfunction with acute encephalopathy, ataxia,
choreoathetosis, developmental delay, severe muscle spastic-
ity and mental retardation, whose neuropathology is poorly
known (Shih et al., 1969; Valle and Simell, 2001).
Interestingly, patients with HHH syndrome and arginine-
mia present similarities in clinical features, with progressive
neurological deterioration and pyramidal signs that are
usually not associated with hyperammonemic decompensa-
tion (Korman et al., 2004; Marescau et al., 1990; Salvi et al.,
2001; Valle and Simell, 2001). Furthermore, it has been
suggested that the lower limb dysfunction observed in HHH
syndrome, and also in argininemia, may be related to an
altered polyamine metabolism (Shimizu et al., 1990).
On the other hand, many individuals with HHH syndrome
present mitochondrial abnormalities, as well as accumulation
and excretion of lactic acid, ketone bodies and CAC intermedi-
ates (Gatfield et al., 1975; Haust et al., 1981; Metoki et al., 1984;
Salvi et al., 2001), indicatingan impairedmitochondrial function.
Therefore, in the current studywe evaluated the in vivo effects of
these amino acids accumulating in HHH syndrome on impor-
tant biochemical parameters of mitochondrial homeostasis,
particularly those related to bioenergetics and biological oxida-
tions in cerebral cortex of young rats in order to provide
mechanistic insights for HHH syndrome neuropathology.
We first verified that Orn and Hcit in vivo administration to
rats increased TBA-RS levels, as compared with control
animals. These results corroborate our previous in vitro
findings (Amaral et al., 2009). Since TBA-RS measurement
reflects the amount of malondialdehyde formation, an end
product of membrane fatty acid peroxidation (Halliwell and
Gutteridge, 2007), the increased values of this parameter
elicited by Orn and Hcit strongly indicates that these amino
acids caused lipid peroxidation in vivo.
Orn, and also Hcit to a higher degree, enhanced carbonyl
formation, implying that they caused protein oxidation. In this
scenario, carbonyl groups (aldehydes and ketones) are mainly
produced by oxidation of protein side chains (especially Pro,Arg, Lys, and Thr), by oxidative cleavage of proteins, or by the
reaction of reducing sugars or their oxidation products with
lysine protein residues (Dalle-Done et al., 2003). However, we
cannot also exclude the possibility that aldehydes resulting
from lipid peroxidation may also induce carbonyl generation
(Dalle-Done et al., 2003).
It was also observed that the antioxidants N-acetylcysteine
(NAC), that forms glutathione intracellularly, and the combina-
tion of the free radical scavengers ascorbic acid plus α-
tocopherol attenuated the lipid oxidation and totally prevented
the protein oxidative damage provoked by Hcit, suggesting that
ROS generation was involved in its effects. As regards to the
reactive species involved inOrnandHcitpro-oxidanteffects, it is
feasible that the peroxyl radical, which is scavenged by α-
tocopherol whose active form is regenerated (reduced) by
ascorbic acid, may underlie at least in part these oxidative
effects. However, considering that NAC also prevented these
effects, we cannot exclude the possibility that a shortage of GSH
could be responsible for lipid and especially protein oxidative
damageprovokedbyHcit andOrn. In fact,wefound thatHcit ICV
administration gave rise to a decrease of GSH concentrations,
besides significantly inhibiting the activity of the antioxidant
enzymes CAT and GPx with no effect on SOD. In contrast, Orn
did not significantly affect any of these antioxidant defenses.
Furthermore, it is unlikely that reactive nitrogen species
participated in the pro-oxidant effects of Orn and Hcit since
these compounds did not elicit nitrate and nitrite synthesis.
Considering that endogenous GSH is considered the major
naturally occurring brain antioxidant and that GPx and CAT
activities are important enzymatic antioxidant defenses (Halli-
well and Gutteridge, 2007), we presume that the rat cortical
antioxidant defenses were compromised by in vivo administra-
tion of Hcit. Furthermore, it is also conceivable that the
reduction of GSH levels may reflect increased reactive species
generation elicited by Hcit. In this context, it may be presumed
that Orn did not reduce GSH levels probably because it induced
less reactive species formation compared toHcit, reflected by its
lower oxidative effects.
Our present data strongly indicate that in vivo administra-
tion of themajor amino acids accumulating in HHH syndrome
induces oxidative stress in rat cerebral cortex since this
deleterious cell condition results from an imbalance between
the total antioxidant defenses and the reactive species
generated in a tissue (Halliwell and Gutteridge, 2007). It should
be emphasized that the brain has low cerebral antioxidant
defenses compared with other tissues (Halliwell and Gutter-
idge, 1996), a fact that makes this tissue more vulnerable to
increased reactive species.
With respect to the parameters of energy metabolism, Orn
and Hcit compromised the aerobic glycolytic pathway and the
CAC activity since they significantly decreased CO2 formation
from labeled glucose and acetate, respectively. It is therefore
possible that Orn and Hcit may have inhibited the activity of
one or more glycolytic enzymes, one or more reactions of the
CAC, and/or the respiratory chain.
We did not determine the activities of the glycolytic
pathway, but measured CAC enzyme activities and the
activities of complexes I–IV of the respiratory chain following
Orn andHcit in vivo administration. Hcit significantly inhibited
aconitase activity, without altering the other enzymes of the
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Considering that aconitase is highly vulnerable to oxidative
damage (Gardner, 1997) and that Hcit provoked a higher
degree of protein oxidative damage compared to Orn, it is
possible that aconitase inhibition may have a result of Hcit-
induced free radical attack to essential groups of the enzyme.
Furthermore, Orn and Hcit significantly reduced the electron
transport chain flow by inhibiting the activity of complex I–III.
Thus, it is feasible that the inhibition of complex I–III activity
by these metabolites and of aconitase by Hcit contributed to
the inhibition of the CAC. Altogether, these findings indicate
that brain bioenergetics associated to energy production is
compromised by Hcit and Orn.
On the other hand, in vivo administration of Hcit and Orn
did not change the activities of creatine kinase (CK) and
synaptic Na+, K+-ATPase from cerebral cortex of rats, which
are important for cell energy buffering and transfer and to
keep the neuronal membrane potential necessary for normal
neurotransmission, respectively.
Altogether, our present findings indicate that Hcit exerted
more significant effects than Orn on most parameters of
oxidative stress and bioenergetics here examined, even
though it was administered at a lower dose (1.6 μmol) as
compared to Orn (5 μmol), reinforcing that Hcit is relatively a
more potent neurotoxin. On the other hand, it seems that the
mild to moderate disruption of bioenergetics and oxidative
damage induced by Orn could hardly be associated with the
neurodegeneration of HHH syndrome since this amino acid
also accumulates at high amounts in ornithine aminotrans-
ferase deficiency, which is characterized by gyrate atrophy of
the choroids and retina, with no alteration of the CNS
(Javadzadeh and Gharabaghi, 2007; Kaiser-Kupfer et al., 1983;
Simell and Takki, 1973).
At the present we cannot determine the pathophysiolog-
ical relevance of the present data since to our knowledge brain
concentrations of Orn and Hcit are not yet established in HHH
syndrome, although blood Orn concentrations may achieve
1 mM during metabolic decompensation in affected patients
(Palmieri, 2008; Valle and Simell, 2001). However, considering
that the present in vivo results are in accordance with previous
in vitro findings, showing that Orn and particularly Hcit disturb
brain bioenergetics (Viegas et al., 2009) and induce oxidative
stress (Amaral et al., 2009), it is presumed that a dual
mechanism, energy deprivation and oxidative damage with
reduction of tissue antioxidant defenses, secondary to acute
accumulation of Hcit and Orn, may contribute to the
neurological dysfunction characteristic of HHH syndrome. It
should be also noted that during stress situations (for
example, episodes of metabolic decompensation) character-
ized by encephalopathy and intense catabolism and proteol-
ysis, much higher concentrations of these amino acids take
place therefore facilitating CNS injury (Camacho et al., 1999).
Our findings showing bioenergetics impairment and oxida-
tive stress caused by the major compounds accumulating in
HHH syndrome may be interrelated since mitochondrial
dysfunction is often associated with large increase of reactive
species generation because oxidative phosphorylation is the
major source of free radicals, which are byproducts of the cell
respiratory cycle (Lemasters et al., 1999). Furthermore, low
energy and oxidative damage are key events facilitating thepathogenic cascade leading to necrotic or apoptotic cell death
especially in neurons, whose viability highly depends on large
amounts of energy to preserve the resting membrane potential
(Kroemer and Reed, 2000; Martin et al., 1994). We cannot also
exclude the possibility that creatine deficiency, that occurs in
OAT deficiency, may also play a role in the neuropathology of
HHH syndrome, but this should be further investigated (Dionisi
Vici et al., 1987; Valayannopoulos et al., 2009).
In summary, the current findings provide insight into
possible mechanisms of brain damage in HHH syndrome
caused in vivo by Hcit and Orn and indicate that the
pathogenesis of this disorder cannot be exclusively attributed
to hyperammonemia. Furthermore, the bioenergetics dys-
function caused by Hcit and Orn may explain the mitochon-
drial abnormalities and the increased urinary excretion of
lactate, 2-hydroxyglutyrate, various CAC intermediates and
glutaric acid that may be observed in patients with HHH
syndrome. Therefore, it is conceivable that, besides a diet poor
in proteins that is chronically used, prompt and aggressive
treatment of infections with high caloric intake (to reduce the
risk of increased catabolism with elevation of brain Orn and
Hcit concentrations) and possibly with antioxidants seems
justified to avoid aggravation of the brain injury in these
patients, especially during acute metabolic decompensation.4. Experimental procedures
4.1. Reagents
All chemicals were purchased from Sigma Chemical Co., St.
Louis, MO, USA, except for [U-14C] glucose and [1-14C] acetate,
which were purchased from Amersham International plc, UK
and homocitrulline, which was obtained from MP Biomedi-
cals, LLC Solon, Ohio, USA. Ornithine, homocitrulline, N-
acetylcysteine, ascorbic acid (vitamin C) and α-tocopherol
(vitamin E) were dissolved in saline solution (NaCl 0.9%).
4.2. Animals
Thirty-day-old Wistar rats obtained from the Central Animal
House of the Departamento de Bioquímica, ICBS, UFRGS, were
used in the assays. The animals had free access to water and
to a standard commercial chow and were maintained on a
12:12-h light/dark cycle in an air-conditioned constant tem-
perature (22±1 °C) colony room. The “Principles of Laboratory
Animal Care” (NIH publication no. 80-23, revised 1996) were
followed in all experiments and the experimental protocol
was approved by the Ethics Committee for Animal Research of
the Federal University of Rio Grande do Sul, Porto Alegre,
Brazil. All efforts were made to minimize the number of
animals used and their suffering.
4.3. Intracerebroventricular (ICV) administration
The ratswere deeply anesthetizedwith ketamine plus xilazine
(75 and 10 mg/kg, i.p., respectively) and placed on a stereotaxic
apparatus. Two small holes were drilled in the skull for
microinjection, and 2 μL of a 2.5 M ornithine solution (5 μmol)
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(1.6 μmol) (pH 7.4 adjustedwith NaOH) or NaCl (controls) at the
same volume and concentration, was slowly injected bilater-
ally over 4 min into the lateral ventricles via needles
connected by a polyethylene tube to a 10-μL Hamilton syringe.
The needles (one in each ventricle) were left in place for
another 1 min before being softly removed. The coordinates
for injections were as follows: 0.6 mm posterior to bregma,
1.1 mm lateral to midline and 3.2 mm ventral from dura
(Paxinos andWatson, 1986). The correct position of the needle
was tested by injecting 0.5 μL of methylene blue injection (4%
in saline solution) and carrying out histological analysis. In
some experiments, the effect of antioxidants on Orn and Hcit-
induced oxidative damage was also evaluated by preinjecting
the animals daily with N-acetylcysteine (NAC, 150 mg/kg, i.p.),
or the combination of α-tocopherol (vitamin E, 40 mg/kg, i.p.)
plus ascorbic acid (vitamin C, 100 mg/kg, i.p.), or saline (NaCl
0.9%, i.p.) for 3 days, after which the animals received an acute
ICV injection of Orn, Hcit or NaCl.4.4. Cerebral cortex preparation
Animals (male rats) were killed by decapitation 30min after ICV
injection of Orn, Hcit or NaCl, and the brain was immediately
removed, the vessels and blood removed, and kept on an ice-
plate. The olfactory bulb, pons andmedulla were discarded and
thecerebral cortexwasdissected,weighedandkept chilleduntil
homogenization. These procedures lasted up to 3 min. For the
determination of oxidative stress parameters, cerebral cortex
was homogenized in 10 volumes (1:10, w/v) of 20mM sodium
phosphate buffer, pH 7.4 containing 140 mMKCl. Homogenates
were centrifuged at 750×g for 10min at 4 °C to discard nuclei
and cell debris (Evelson et al., 2001). The pellet was discarded
and the supernatant containingmitochondriawas immediately
separated and used for the measurements.
For CO2 production, the cerebral cortex was homogenized
(1:10, w/v) in Krebs–Ringer bicarbonate buffer, pH 7.4. For the
determination of the activities of the respiratory chain com-
plexes I–III, II, II–III and IV and theCAC enzymes, cerebral cortex
was homogenized (1:20, w/v) in SETH buffer, pH 7.4 (250mM
sucrose, 2.0 mM EDTA, 10mM Trizma base and 50 UI mL−1
heparin). The homogenate was centrifuged at 800×g for 10min
and the supernatant was kept at −70 °C until being used for
enzymatic activity determination. For creatine kinase activity
determination, the cerebral cortex was homogenized (1:10 w/v)
in isosmotic saline solution. The period between tissue prepa-
ration andmeasurement of the various parameters was always
less than 5 days, except for CO2 production assays, whose
experiments were performed on the same day of the
preparations.4.5. Preparation of synaptic plasma membrane from rat
cerebral cortex
Cerebral cortex was homogenized in 10 volumes of 0.32 mM
sucrose solution containing 5.0 mM HEPES and 1.0 mM EDTA.
Membranes were prepared according to the method of Jones
and Matus (1974) using a discontinuous sucrose density
gradient consisting of successive layers of 0.3, 0.8 and1.0 mM. After centrifugation at 69,000×g for 2 h, the fraction
at the 0.8–1.0 mM sucrose interface was taken as the
membrane enzyme preparation.
4.6. Oxidative stress parameters
4.6.1. Determination of thiobarbituric acid-reactive substances
(TBA-RS)
TBA-RS levels were measured according to the method
described by Yagi (1998) with slight modifications. Briefly,
200 μL of 10% trichloroacetic acid and 300 μL of 0.67% TBA in
7.1% sodium sulfate were added to 100 μL of tissue superna-
tant and incubated for 2 h in a boiling water bath. Themixture
was allowed to cool on running tap water for 5 min. The
resulting pink-stained complex was extracted with 400 μL of
butanol. Fluorescence of the organic phase was read at 515
and 553 nm as excitation and emission wavelengths, respec-
tively. Calibration curve was performed using 1,1,3,3-tetra-
methoxypropane and subjected to the same treatment as
supernatants. TBA-RS levels were calculated as nmol TBA-RS/
mg protein.
4.6.2. Determination of sulfhydryl (thiol) content
This assay is based on the reduction of 5,5′-dithio-bis (2-
nitrobenzoic acid; DTNB) by thiols, generating a yellow
derivative (TNB), whose absorption is measured spectropho-
tometrically at 412 nm (Aksenov and Markesbery, 2001).
Briefly, 30 μL of 10 mM DTNB and 980 μL of PBS were added
to 50 μL of cerebral cortex supernatants. This was followed by
30-min incubation at room temperature in a dark room.
Absorption was measured at 412 nm. Results are reported as
nmol TNB/mg protein.
4.6.3. Determination of protein carbonyl formation
Protein carbonyl content formation, a marker of oxidized
proteins, was measured spectrophotometrically according to
Levine et al. (1994) and Reznick and Packer (1994). One
hundred microliters of the aliquots from the incubation was
treated with 400 μL of 10 mM 2,4-dinitrophenylhidrazine
(DNPH) dissolved in 2.5 N HCl or with 2.5 N HCl (blank control)
and left in the dark for 1 h. Samples were then precipitated
with 500 μL 20% TCA and centrifuged for 5 min at 10,000×g.
The pellet was then washed with 1 mL ethanol/ethyl acetate
(1:1, v/v) and re-dissolved in 550 μL 6 M guanidine prepared in
2.5 N HCl. Then, the tubes were incubated at 37 °C for 5 min to
assure the complete dissolution of the pellet and the resulting
sample was determined at 365 nm. The difference between
the DNPH-treated and HCl-treated samples was used to
calculate the carbonyl content. The results were calculated
as nmol of carbonyls groups/mg of protein, using the
extinction coefficient of 22,000×106 nmol/mL for aliphatic
hydrazones.
4.6.4. Determination of nitrate and nitrite content
Nitrate and nitrite concentrations were determined according
to Miranda et al. (2001). Briefly, 12 μL of 20% trichloroacetic
acid was added to 300 μL of cerebral cortex supernatants and
centrifuged at 12,000×g for 10 min. Two hundred microliters
of the supernatant was transferred to an eppendorf tube and
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Griess reagent (2% sulfanilamide in 5% HCl and 0.1% N-1-
(naphtyl)ethylenediamine in H2O) at 37 °C for 30 min in a dark
room. Absorbance was then determined at 540 nm by
spectrophotometry. A calibration curve was performed using
sodium nitrate. Each curve point was subjected to the same
treatment as supernatants and the concentrations were
calculated as mmol/mg protein.
4.6.5. Determination of reduced glutathione (GSH) levels
GSH levels were evaluated according to Browne and Armstrong
(1998). Tissue supernatants were diluted in 20 volumes (1:20, v/
v) of 100mM sodium phosphate buffer pH 8.0, containing 5 mM
EDTA. One hundred microliters of this preparation was
incubated with an equal volume of o-phthaldialdehyde (1mg/
mL methanol) at room temperature for 15 min. Fluorescence
was measured using excitation and emission wavelengths of
350 and 420 nm, respectively. Calibration curve was performed
with standard GSH (0.001–0.1 mM), and GSH concentrations
were calculated as nmol/mg protein.
4.6.6. Determination of glutathione peroxidase (GPx) activity
GPx activity was measured according to Wendel (1981) using
tert-butylhydroperoxide as substrate. The enzyme activity was
determined by monitoring the NADPH disappearance at
340 nm in amediumcontaining 100 mMpotassiumphosphate
buffer/1 mM ethylenediaminetetraacetic acid, pH 7.7, 2 mM
GSH, 0.1 U/mL glutathione reductase, 0.4 mM azide, 0.5 mM
tert-butyl-hydroperoxide, 0.1 mM NADPH, and the superna-
tant containing 0.2–0.4 mg protein/mL. One GPx unit (U) is
defined as 1 μmol of NADPH consumed per minute. The
specific activity was calculated as U/mg protein.
4.6.7. Determination of catalase (CAT) activity
CAT activity was assayed according to Aebi (1984) by
measuring the absorbance decrease at 240 nm in a reaction
medium containing 20 mM H2O2, 0.1% Triton X-100, 10 mM
potassium phosphate buffer, pH 7.0, and the supernatants
containing 0.05–0.1 mg protein/mL. One unit (U) of the enzyme
is defined as 1 μmol of H2O2 consumed per minute. The
specific activity was calculated as U/mg protein.
4.6.8. Determination of superoxide dismutase (SOD) activity
SOD activity was assayed according to Marklund (1985) and is
based on the capacity of pyrogallol to autoxidize, a process highly
dependent on O2•−, which is a substrate for SOD. The inhibition of
autoxidation of this compound occurs in the presence of SOD,
whose activity can be then indirectly assayed spectrophotomet-
rically at 420 nm. The reaction medium contained 50mM Tris
buffer/1 mM ethylenediaminetetraacetic acid, pH 8.2, 80 U/mL
catalase, 0.38 mM pyrogallol and supernatants containing 0.1–
0.2 mg protein/mL. A calibration curve was performed with
purified SOD as standard to calculate the activity of SOD present
in the samples. The results are reported as U/mg protein.
4.7. Energy metabolism parameters
4.7.1. Determination of CO2 production
Homogenates prepared in Krebs–Ringer bicarbonate buffer, pH
7.4, were added to small flasks (11 cm3) in a volume of 0.45 mL.Flasks were pre-incubated at 35 °C for 10 min in a metabolic
shaker (90 oscillations min−1) with 625 μM n-dodecyl-β-D-
maltoside in order to permeabilize the mitochondrial mem-
branes. After pre-incubation, [U-14C] glucose (0.055 μCi) plus
5.0 mM of unlabeled glucose or 0.055 μCi [1-14C] acetate plus
1.0 mM of unlabeled acetate were added to the incubation
medium. The flasks were gassed with a O2/CO2 (95:5) mixture
and sealedwith rubber stoppers ParafilmM. Glass center wells
containing a folded 60 nm/4 nm piece of Whatman 3 filter
paper were hung from the stoppers. After 60 min incubation at
35 °C in a metabolic shaker (90 oscillations min−1), 0.2 mL of
50% trichloroacetic acid was supplemented to the medium
and 0.1 mL of benzethonium hydroxide was added to the
center of thewells with needles introduced through the rubber
stopper. The flasks were left to stand for 30 min to complete
CO2 trapping and then opened. The filter paper were removed
and added to vials containing scintillation fluid, and radioac-
tivity was counted (Assis et al., 2004). Results were calculated
as pmol CO2 h−1 g tissue−1.4.7.2. Spectrophotometric analyses of the activities of citric
acid cycle (CAC) enzymes
Citrate synthase activity was measured according to Srere
(1969), by determining DTNB reduction at λ=412 nm. The
activity of the enzyme aconitase was measured according to
Morrison (1954), following the reduction of NADP+ at wave-
lengths of excitation and emission of 340 and 466 nm,
respectively. Isocitrate dehydrogenase activity was accessed
by the method of Plaut (1969), by following NAD+ reduction at
wavelengths of excitation and emission of 340 and 466 nm,
respectively. The activity of α-ketoglutarate dehydrogenase
complex was evaluated according to Viegas et al. (2009). The
reduction of NAD+ was recorded in a Hitachi F-4500 spectro-
fluorometer at wavelengths of excitation and emission of 340
and 466 nm, respectively. The activity of succinate dehydro-
genase was determined as described by Fischer et al. (1985).
Fumarase activity was measured according to O'Hare and
Doonan (1985), measuring the increase of absorbance at
λ=250 nm. Malate dehydrogenase activity was measured
according to Kitto (1969) by following the reduction of NADH
at wavelengths of excitation and emission of 340 and 466 nm,
respectively. The activities of the CAC enzymes were calcu-
lated as nmolmin−1 mg protein−1, mmolmin−1 mg protein−1 or
μmol min−1 mg protein−1.4.7.3. Spectrophotometric analysis of the respiratory chain
complex I–IV activities
The activities of succinate-2,6-dichloroindophenol (DCIP)-
oxidoreductase (complex II) and succinate/cytochrome c
oxidoreductase (complex II–III) were determined according to
Fischer et al. (1985). The activity of NADH/cytochrome c
oxidoreductase (complex I–III) was assayed according to the
method described by Schapira et al. (1990) and that of
cytochrome c oxidase (complex IV) according to Rustin et al.
(1994). The methods described to measure these activities
were slightly modified, as described in details in a previous
report (Silva et al., 2002). The activities of the respiratory chain
complexes were calculated as nmol min−1 mg protein−1 or
mmol min−1 mg protein−1.
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activity
CK activity was measured according to Hughes (1962) with
slight modifications (Schuck et al., 2002). Briefly, the reaction
mixture consisted of 50 mM Tris buffer, pH 7.5, containing
7.0 mM phosphocreatine, 7.5 mM MgSO4, and 0.5–1.0 μg pro-
tein in a final volume of 0.1 mL. The reaction was then started
by addition of 4.0 mM ADP and stopped after 10 min by
addition of 0.02 mL of 50 mM p-hydroxy-mercuribenzoic
acid. The creatine formed was estimated according to the
colorimetric method of Hughes (1962). The color was devel-
oped by the addition of 0.1 mL 20% α-naphtol and 0.1 mL 20%
diacetyl in a final volume of 1.0 mL and read after 20 min at
λ=540 nm. Results were calculated as μmol of creatine min−1
mg protein−1.4.7.5. Spectrophotometric analysis of Na+, K+-ATPase activity
The reaction mixture for the Na+, K+-ATPase assay contained
5 mMMgCl2, 80 mM NaCl, 20 mM KCl, 40 mM Tris–HCl buffer,
pH 7.4, and purified synapticmembranes (approximately 3 μg
of protein) in a final volume of 200 μL. The enzymatic assay
occurred at 37 °C during 5 min and started by the addition of
ATP (disodium salt, vanadium free) to a final concentration of
3 mM. The reaction was stopped by the addition of 200 μL of
10% trichloroacetic acid. Mg2+-ATPase ouabain-insensitive
was assayed under the same conditions with the addition of
1 mM ouabain. Na+, K+-ATPase activity was calculated by the
difference between the two assays (Tsakiris and Delicon-
stantinos, 1984). Released inorganic phosphate (Pi) was
measured by the method of Chan et al. (1986). Enzyme-
specific activities were calculated as nmol Pi released−1 min−1
mg protein.4.8. Protein determination
Protein was measured by the methods of Lowry et al. (1951)
using bovine serum albumin as standard.4.9. Statistical analysis
Unless otherwise stated, results are presented as mean±
standard deviation. Assays were performed in duplicate or
triplicate and the mean or median was used for statistical
analysis. Data was analyzed using one-way analysis of
variance (ANOVA) followed by the post-hoc Duncan multiple
range test when Fwas significant. Only significant F values are
shown in the text. Differences between groups were rated
significant at p<0.05. All analyses were carried out in an IBM-
compatible PC computer using the Statistical Package for the
Social Sciences (SPSS) software.Acknowledgments
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